Pharmacokinetic Study of β-Methyldigoxin by Enzyme Immunoassay Using a Novel Specific Antiserum in Rats

We previously showed that enzyme immunoassay (EIA) of β-methyldigoxin (MDx3) using anti-MDx3 3′-hemisuccinate–bovine serum albumin antiserum (Antiserum-I) was superior to that using commercial anti-digoxin antiserum (Antiserum-II) in terms of specificity and that pretreatment of human serum with phe...

Full description

Saved in:
Bibliographic Details
Published in:Biological & pharmaceutical bulletin Vol. 26; no. 2; pp. 247 - 251
Main Authors: Higashi, Yasuhiko, Watanabe, Naomi, Sasaki, Toshiyuki, Fujii, Youichi
Format: Journal Article
Language:English
Published: Tokyo The Pharmaceutical Society of Japan 01-02-2003
Maruzen
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We previously showed that enzyme immunoassay (EIA) of β-methyldigoxin (MDx3) using anti-MDx3 3′-hemisuccinate–bovine serum albumin antiserum (Antiserum-I) was superior to that using commercial anti-digoxin antiserum (Antiserum-II) in terms of specificity and that pretreatment of human serum with phenyl boric acid (PBA) column was effective. In the present study, we examined the precision of EIA using Antiserum-I and the recovery of MDx3 after PBA column treatment in rat serum, and also investigated pharmacokinetic changes of MDx3 in rats. The intra- and inter-assay variations and recovery tests using Antiserum-I were good. The PBA column was effective in selectively separating MDx3 from rat serum containing MDx3 and its metabolites. The recovery tests using Antiserum-I with PBA column showed about 110% and the interference of metabolites of MDx3 was negligible. Serum concentration–time courses of MDx3 by EIA using Antiserum-I with PBA column and Antiserum-I were lower than that using Antiserum-II. The distribution volume at steady state and total body clearance values of MDx3 in these conditions were significantly higher than those using Antiserum-II. The usefulness of PBA column was ascertained, while effects of PBA column on these parameters were not significant. In addition, rapid absorption of MDx3 was observed by EIA using Antiserum-I with PBA column. These results suggest that EIA using Antiserum-I with PBA column for the pretreatment of serum samples should be a more useful and valuable system in therapeutic drug monitoring and pharmacokinetic studies of the unchanged type of MDx3 than Antiserum-II.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0918-6158
1347-5215
DOI:10.1248/bpb.26.247